MedTrace Logo

Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

NCT04137588 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 126

Last updated 2021-02-24

No results posted yet for this study

Summary

The purpose of this study is to explore the efficacy and safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Conditions

  • Advanced Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG

Antiangiogenesis Agents

antiangiogenesis agents plus chemotherapy as first line treatment

DRUG

Immune checkpoint inhibitor

immune checkpoint inhibitor plus chemotherapy as first line treatment

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2022-03-01
Completion
2022-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04137588 on ClinicalTrials.gov